Previous Close | 2.97 |
1-Year Change | 49.25% |
6-Months Change | 85.62% |
3-Months Change | 15.12% |
Moving Avg (50d) | 2.3109 |
Moving Avg (200d) | 2.0552 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 64.5M |
Beta (3-Years) | 1.32 |
Revenue Growth (ttm) | 27.61% |
Net Profit Margin (ttm) | -31427.49% |
Return On Assets (ttm) | -2422.95% |
EPS (ttm) | -4.54 |
PE Ratio (ttm) | -0.65 |
Dividend Yield | % |
Asset Description: | Checkpoint Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-10-17 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
2.911 | 2.822 | 2.762 | 2.673 | 2.525 | 2.376 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.